「the」の検索結果
159件：81～85件目を表示
-
ers: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this &qu...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf -
. Launch and Distribution of “MIEr for BeelineMED” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for BeelineMED” in Japan. MIEr for BeelineMED is cap...
https://www.senju.co.jp/system/files/content_news/2025-02/ENG_20250220.pdf -
. Launch and Distribution of “MIEr for BeelineMED” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for BeelineMED” in Japan. MIEr for BeelineMED is cap...
https://www.senju.co.jp/system/files/content_news/2025-02/ENG_20250220_0.pdf -
; hereinafter “Senju”) hereby announces that it has entered into a LicensingAgreement for Corneal Esthesiometer Brill in Japan with Brill International (Headquarters: Barcelona, Spain; CEO: Jordi Mart...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307_0.pdf -
お知らせ | 千寿製薬株式会社
August 20, 2026 Senju initiated Phase III Clinical Trials in Japan for "SJP-0049" for the treatment of Allergic Conjunctivitis（PDF） June 1, 2026 Launch of Distribution of 3in1Smart and SPM-7...
http://www.senju.co.jp/english/news/